Intensive care medicine · 2006
Serum S-100B protein monitoring in patients with severe traumatic brain injury.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Korfias Stefanos, Stranjalis George, Boviatsis Efstathios, Psachoulia Christina, Jullien Gerard, Gregson Barbara, Mendelow A David, Sakas Damianos E
Аннотация
OBJECTIVE: S-100B protein is a promising marker of injury severity and outcome after head injury. We examined the relationship between serum S-100B concentrations and injury severity, clinical course, survival, and treatment efficacy after severe traumatic brain injury (TBI).
DESIGN AND SETTING: Prospective observational study in a neurosurgical intensive care unit.
PATIENTS AND PARTICIPANTS: 102 adult patients with severe TBI, admitted between June 2001 and November 2003 (30 months).
INTERVENTIONS: Serum S-100B levels were measured by immunoluminometric technique on admission and every 24 h thereafter for a maximum of 7 days.
MEASUREMENTS AND RESULTS: Initial S-100B levels were significantly related to pupillary status, computed tomography severity 1, and 1-month survival. Cox's proportional hazard regression analysis showed that initial S-100B was an independent predictor of 1-month survival, in the presence of dilated pupils, and with increased age. Subjects with initial levels above 1 microg/l had a nearly threefold increased probability of death within 1 month. Serum S-100B alteration indicated neurological improvement or deterioration. Finally, surgical treatment reduced S-100B levels.
CONCLUSIONS: Serum S-100B protein reflects injury severity and improves prediction of outcome after severe TBI. S-100B may also have a role in assessing the efficacy of treatment after severe TBI.
DESIGN AND SETTING: Prospective observational study in a neurosurgical intensive care unit.
PATIENTS AND PARTICIPANTS: 102 adult patients with severe TBI, admitted between June 2001 and November 2003 (30 months).
INTERVENTIONS: Serum S-100B levels were measured by immunoluminometric technique on admission and every 24 h thereafter for a maximum of 7 days.
MEASUREMENTS AND RESULTS: Initial S-100B levels were significantly related to pupillary status, computed tomography severity 1, and 1-month survival. Cox's proportional hazard regression analysis showed that initial S-100B was an independent predictor of 1-month survival, in the presence of dilated pupils, and with increased age. Subjects with initial levels above 1 microg/l had a nearly threefold increased probability of death within 1 month. Serum S-100B alteration indicated neurological improvement or deterioration. Finally, surgical treatment reduced S-100B levels.
CONCLUSIONS: Serum S-100B protein reflects injury severity and improves prediction of outcome after severe TBI. S-100B may also have a role in assessing the efficacy of treatment after severe TBI.